IC
ARCT icon

Innealta Capital’s Arcturus Therapeutics ARCT Stock Holding History

Innealta Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24
Closed -$584 – 254
2024
Q2 		$584 Buy
+24
New +$728 ﹤0.01% 1445

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Innealta Capital's ARCT Position: Q3 2024 in Review

Innealta Capital sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 24 shares — an estimated $584 sold.

Innealta Capital first reported a position in ARCT in Q2 2024 and held it in 1 quarter. The position peaked at $584 in Q2 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Innealta Capital reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 24 Arcturus Therapeutics shares in Q3 2024, an estimated $584.
  • Innealta Capital first reported a position in Arcturus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Arcturus Therapeutics position peaked at $584 in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.